



# Are you living with Progressive Pulmonary Fibrosis (PPF)?

If so, you may be eligible for a clinical research study. The IM0271015 (ALOFT-PPF) study is testing an investigational drug called BMS-986278 (the “study drug”) as a potential new treatment for PPF.

Treatments available today can help, but for some people PPF gets worse despite treatment<sup>1</sup>. There is a need for continued research to identify potential new treatments.

## About the ALOFT-PPF study

**This clinical research study is evaluating the study drug to learn more about its:**

- Safety
- Tolerability (how the body reacts)
- Effect on PPF progression

**You may qualify to participate in this study if you:**

- Are 21 years of age or older
- Have been diagnosed with pulmonary fibrosis that has an identifiable cause and has progressed (gotten worse) or is at high risk of progression
- Have not had lung reduction surgery or lung transplantation

*Additional eligibility requirements will be checked as part of study screening.*

If you qualify and choose to participate, you will NOT be charged for the study drug, visits, tests, and procedures necessary for the study per the study protocol.

Participation is voluntary; you will be free to stop at any time.

**To learn more about the ALOFT-PPF study, please contact:**

**PI-Dr. Priya Ramachandran**

**St. John's Medical College & Hospital,  
Bangalore.**

[priya.r@st.johns.in](mailto:priya.r@st.johns.in)

**08022065802**

<sup>1</sup> Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *N Engl J Med.* 2019;381(18):1718-27.